Published in J Gen Virol on September 01, 2006
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology (2014) 1.61
Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem (2008) 1.49
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. J Virol (2008) 1.23
The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. Hepatology (2009) 1.19
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Transcriptome analysis on Chinese shrimp Fenneropenaeus chinensis during WSSV acute infection. PLoS One (2013) 1.14
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J Virol (2009) 1.04
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol (2007) 0.95
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
The second extracellular loop dictates Occludin-mediated HCV entry. Virology (2010) 0.92
Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol (2012) 0.92
New treatments for chronic hepatitis C. Korean J Hepatol (2010) 0.89
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol (2013) 0.85
AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol (2015) 0.85
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. J Virol (2015) 0.83
In vitro systems for the study of hepatitis C virus infection. Int J Hepatol (2012) 0.82
Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J Innate Immun (2009) 0.80
A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog (2011) 0.80
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine (2010) 3.28
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.96
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg (2006) 2.70
A review of vaccine research and development: meningococcal disease. Vaccine (2006) 2.64
Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology (2011) 2.51
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology (2013) 2.28
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol (2003) 2.23
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10
Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas (2008) 2.05
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
A review of human vaccine research and development: malaria. Vaccine (2006) 1.95
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 1.71
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology (2010) 1.65
Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med (2014) 1.64
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med (2014) 1.61
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
The impact of globalization on vaccine development and availability. Health Aff (Millwood) (2006) 1.58
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg (2007) 1.51
Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Surg (2009) 1.50
A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine (2006) 1.48
A review of vaccine research and development: human enteric infections. Vaccine (2005) 1.46
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Inferior vena cava graft-enteric fistula after extended hepatectomy with caval replacement. J Vasc Surg (2011) 1.45
Splenic vein-inferior mesenteric vein anastomosis to lessen left-sided portal hypertension after pancreaticoduodenectomy with concomitant vascular resection. Arch Surg (2011) 1.43
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol (2010) 1.42
Prediction of mortality rate after major hepatectomy in patients without cirrhosis. Arch Surg (2010) 1.42
Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J Surg (2010) 1.40
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial. BMC Cancer (2012) 1.40
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol (2008) 1.36
Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg (2007) 1.36
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Outcome after pancreaticoduodenectomy for cancer in elderly patients. J Gastrointest Surg (2006) 1.34
Hepatitis C virus entry: molecular biology and clinical implications. Hepatology (2006) 1.34
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine (2010) 1.29
A review of vaccine research and development: human acute respiratory infections. Vaccine (2005) 1.27
Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl (2003) 1.24
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 1.22
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis (2009) 1.21
Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy. PLoS Negl Trop Dis (2012) 1.21
Pancreaticogastrostomy decreased relaparotomy caused by pancreatic fistula after pancreaticoduodenectomy compared with pancreaticojejunostomy. Arch Surg (2004) 1.21
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol (2012) 1.18
Hepatitis C virus entry. Curr Top Microbiol Immunol (2013) 1.17
Global production capacity of seasonal influenza vaccine in 2011. Vaccine (2012) 1.17
Medial pancreatectomy: a multi-institutional retrospective study of 53 patients by the French Pancreas Club. Surgery (2002) 1.17
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology (2008) 1.16
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol (2005) 1.14
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology (2012) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis (2006) 1.11
Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (2005) 1.11
Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest (2002) 1.11
Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc Natl Acad Sci U S A (2008) 1.09
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology (2008) 1.08
Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med (2010) 1.07
Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. Surgery (2008) 1.07
The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology (2012) 1.07
Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology (2012) 1.06
Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One (2009) 1.05
A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis (2012) 1.05
Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine (2008) 1.05
Mouse models for the study of HCV infection and virus-host interactions. J Hepatol (2008) 1.05
A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One (2013) 1.04